Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Samsara Inc (IOT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Samsara Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Samsara Inc trades at $35.88 (market cap $21.18B). The key difference: Samsara Inc is far larger — about 4.7× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Samsara Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | IOT | |
|---|---|---|
Market Cap | $4.49B | $21.18B |
Sector | Health | Technology |
52-Week High | $28.06 | $45.22 |
52-Week Low | $20.06 | $24.25 |
Enterprise Value | $3.69B | $20.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Samsara (IOT) trades at $37.51, up 4.4% with strong bullish technical signals and consistent earnings beats. The company shows robust revenue growth projection from $1.25B (2025) to $1.7B (2026) and improving profitability, though current valuation metrics remain elevated with P/E of 375. Recent product launches including tracking labels and AI capabilities demonstrate innovation momentum in the connected operations space.
While analyst consensus remains strongly bullish with 78% buy ratings and $44.40 price target, investors face valuation concerns and execution risks as the company transitions toward profitability. The stock's technical overbought condition near resistance levels suggests potential near-term consolidation before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Samsara Inc
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →
